{
    "clinical_study": {
        "@rank": "152862", 
        "arm_group": [
            {
                "arm_group_label": "PLX-PAD Low dose", 
                "arm_group_type": "Experimental", 
                "description": "PLX-PAD double low doses"
            }, 
            {
                "arm_group_label": "PLX-PAD high doses", 
                "arm_group_type": "Active Comparator", 
                "description": "PLX-PAD double high dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Double Placebo doses"
            }, 
            {
                "arm_group_label": "PLX-PAD high dose +Placebo", 
                "arm_group_type": "Experimental", 
                "description": "High dose+Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the study is to establish the safety profile of\n\n      Intramuscular PLX-PAD injections and to evaluate the clinical efficacy of it in IC subjects\n      comprising of 4 treatment groups:\n\n        1. Double treatment of PLX-PAD low dose\n\n        2. Double treatment of PLX-PAD high dose\n\n        3. Double treatment of Placebo\n\n        4. Single treatment of PLX-PAD high dose and additional treatment of Placebo. Subjects\n           will receive the assigned treatment twice to the affected leg, within  12-weeks\n           interval between each treatment.\n\n      The study will be comprised of 5 stages:\n\n      Screening period of up to 4 weeks,first treatment of PLX-PAD or placebo followed by\n      additional injection after 12 weeks and with follow-up of 12 months post second injection"
        }, 
        "brief_title": "Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)", 
        "condition": [
            "Intermittent Claudication", 
            "Peripheral Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Intermittent Claudication", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female subjects between 45 to 80 years of age (inclusive) at the time\n             of screening visit.\n\n          -  Subjects with a diagnosis of peripheral artery disease, secondary to atherosclerosis,\n             confirmed by one of the following criteria assessed at the screening visit:\n\n               -  Resting ankle-brachial index (ABI) \u2264 0.80 or\n\n               -  Resting ABI \u2264 0.90 and >20% decrease in ABI from rest to exercise when measured\n                  within 1 minute after treadmill exercise or\n\n               -  Toe-brachial index (TBI) \u2264 0.60\n\n          -  Lifestyle-limiting, moderate to severe claudication (symptoms present and stable for\n             > 6 months and not significantly changed within the past 3 months prior to\n             screening).\n\n          -  Evidence of significant (>50%) stenosis infra-inguinal occlusive disease as confirmed\n             by documented results from Duplex, MRA, CTA and/or contrast angiogram completed\n             within 3 months prior to screening.\n\n          -  The longest maximal walking distance (MWD) from the Screening Period exercise\n             treadmill tests (ETT), utilizing a modified Gardner Protocol (Appendix I), must be\n             between 1 and 10 minutes (inclusive).\n\n          -  Subjects who have persistent claudication symptoms despite having been recommended an\n             exercise program if feasible, and or despite having been on a stable dose of\n             Cilostazol, if indicated. Subjects should be Cilostazol free for at least 2 weeks\n             prior to the first ETT.\n\n          -  Subjects should be receiving standard of care drugs for vascular disease including\n             anti-platelet agent(s) and statin medication, as well as anti-hypertensive\n             medication(s) and oral hypoglycemic agents/insulin, if indicated.\n\n          -  Signed written informed consent.\n\n        Exclusion Criteria:\n\n          -  Ischemic rest pain; ulceration or gangrene (Fontaine class III-IV; Rutherford\n             category 4-6).\n\n          -  Failed lower extremity arterial reconstruction (surgical or endovascular) or\n             sympathectomy within the prior one month of screening.\n\n          -  Planned revascularization (surgical or endovascular intervention) within 12 months\n             after screening.\n\n          -  Lower extremity arteries inflow obstruction (defined as a greater than 50%  stenosis\n             of aorta, iliac and/or common femoral arteries).\n\n          -  History of Buerger's disease.\n\n          -  Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or systolic\n             blood pressure > 180 mmHg during screening).\n\n          -  Uncontrolled diabetes defined as glucose control HbA1c > 9% at screening.\n\n          -  Life-threatening ventricular arrhythmia - except in subjects with an implantable\n             cardiac-defibrillator.\n\n          -  Serum Creatinine level>2.5mg/dl.\n\n          -  SGPT (ALT), SGOT (AST) >2.5 x upper limit of normal range.\n\n          -  Hemoglobin < 10 g/dl.\n\n          -  Unstable cardiovascular disease defined as myocardial infarction (STEMI or NSTEMI)\n             within 3 months prior to screening, or unstable angina - characterized by\n             increasingly frequent episodes with modest exertion or at rest, worsening severity,\n             and prolonged episodes.\n\n          -  Transient Ischemic Attack (TIA)/Stroke within 3 months prior to screening.\n\n          -  Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage III to IV).\n\n          -  Subjects with Implant of mechanical prosthetic heart valve(s).\n\n          -  Pulmonary disease requiring supplemental oxygen treatment on a daily basis.\n\n          -  Severe, active infection of the involved extremity(ies), including osteomyelitis,\n             fasciitis, or severe/purulent cellulitis.\n\n          -  History of malignancy within 5 years prior screening requiring chemotherapy and/or\n             radiotherapy and/or immunotherapy, excluding basal or squamous cell carcinoma of the\n             skin.\n\n          -  Exercise is limited by any condition other than IC, including but not limited to\n             congestive heart failure, chronic pulmonary disease, angina pectoris, or degenerative\n             joint disease.\n\n          -  Uninterrupted use of warfarin or non-steroidal anti-inflammatory agents (with the\n             exception of ibuprofen at doses up to 1,200 mg/day or Diclofenac at dose of\n             75mg/day).\n\n          -  Subjects who are on oral anticoagulant therapy (warfarin, dabigatran, apixaban,\n             endoxaban and rivaroxaban).  Unless, upon primary care physician and/or\n             Investigator's discretion the subjects who are on warfarin treatment can switch to\n             Low Molecular Weight Heparin treatment (such as: Clexane) 5-7 days prior study\n             treatment administration and return to warfarin treatment 24 hours post study\n             treatment administration.\n\n          -  Subjects who are taking immunosuppressive treatment (including high dose steroids).\n\n          -  Known allergies to protein products (Bovine serum, or recombinant trypsin) used in\n             the cell production process.\n\n          -  Known sensitivity to Gentamycin.\n\n          -  Known sensitivity to antihistamine drugs.\n\n          -  History of hospitalization due to allergic/hypersensitivity reaction to any substance\n             (e.g. Food or drug).\n\n          -  Medical history of Human Immunodeficiency Virus (HIV) or syphilis positivity at time\n             of screening.\n\n          -  Known active Hepatitis B, or Hepatitis C infection at the time of screening.\n\n          -  Pregnant or breast-feeding women or women of childbearing age not protected by an\n             effective contraceptive method of birth control (such as double barrier, oral or\n             parenteral hormonal, intrauterine device and spermicide).\n\n          -  In the opinion of the Investigator, the subject is unsuitable for participating in\n             the study.\n\n          -  Subject is currently enrolled in, or has not yet completed a period of at least 30\n             days since ending other investigational device or drug trial(s).\n\n          -  Subjects that have prior exposure to gene or cell based therapy.\n\n          -  Subjects who are legally detained in an official institute."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679990", 
            "org_study_id": "PLX 1204-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "PLX-PAD Low dose", 
                "intervention_name": "PLX-PAD Low dose", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PLX-PAD high doses", 
                "intervention_name": "PLX-PAD high doses", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Double Placebo", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "PLX-PAD high dose +Placebo", 
                "intervention_name": "high dose +Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 9, 2013", 
        "location": [
            {
                "contact": {
                    "email": "hampsey@tbmr.net", 
                    "last_name": "James Hampsey, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33761"
                    }, 
                    "name": "Tampa Bay Medical Research"
                }, 
                "investigator": {
                    "last_name": "James Hampsey, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kurtm@flrnetwork.com", 
                    "last_name": "Kurt Malphurs, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32605"
                    }, 
                    "name": "Florida Researc Network, LLC"
                }, 
                "investigator": {
                    "last_name": "Bret Weichmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kcullen@dmiresearch.com", 
                    "last_name": "Kathleen Cullen, MD", 
                    "phone": "727-531-2848"
                }, 
                "facility": {
                    "address": {
                        "city": "Pinellas Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33782"
                    }, 
                    "name": "DMI Research"
                }, 
                "investigator": {
                    "last_name": "Kathleen Cullen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jnadarajah@pol.net", 
                    "last_name": "Nadarajah Janaki, MD", 
                    "phone": "706-868-0319"
                }, 
                "facility": {
                    "address": {
                        "city": "Evans", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Dr. Nadarajah Janaki"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ssaha2@email.uky.edu", 
                    "last_name": "Sibu P. Saha, MD", 
                    "phone": "859-257-8250"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40506-0057"
                    }, 
                    "name": "University of Kentucky Research Foundation"
                }, 
                "investigator": {
                    "last_name": "Sibu P Saha, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Hirsc005@umn.edu", 
                    "last_name": "Alan T Hirsch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "Cardiovascular Division, MMC, University of Minnesota"
                }, 
                "investigator": {
                    "last_name": "Alan T Hirsch, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jeffrey.olin@mountsinai.org", 
                    "last_name": "Jeffrey W Olin, DO"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Cardiovascular Institute, Mount Sinai School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Jeffrey W Olin, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "schuyler.jones@dm.duke.edu", 
                    "last_name": "Jones Schulyer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "Jones Schulyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Emile.Mohler@uphs.upenn.edu", 
                    "last_name": "Mohler Emile, M.D", 
                    "phone": "215-662-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Dr. Mohler Emile"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dr.fried@omegamedicalresearch.com", 
                    "last_name": "David L Fried, MD", 
                    "phone": "401-739-9350"
                }, 
                "facility": {
                    "address": {
                        "city": "Warwick", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02886"
                    }, 
                    "name": "Omega Medical Center"
                }, 
                "investigator": {
                    "last_name": "David L Fried, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "malcolm.foster@etc.com", 
                    "last_name": "Malcolm Foster, MD", 
                    "phone": "865-218-7535"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "10820"
                    }, 
                    "name": "Turkey Creek Medical Center"
                }, 
                "investigator": {
                    "last_name": "Malcolm Foster, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ddenham@cttexas.com", 
                    "last_name": "Douglas Denham, DO"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Clinical Trials of Texas"
                }, 
                "investigator": {
                    "last_name": "Douglas Denham, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "andre.schmidt-lucke@franziskus-berlin.de", 
                    "last_name": "Andr\u00e9 Schmidt-Lucke, MD", 
                    "phone": "+493026383600"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Franziskus-Krankenhaus"
                }, 
                "investigator": {
                    "last_name": "Andr\u00e9 Schmidt-Lucke, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Norbert.Weiss@uniklinikum-dresden.de", 
                    "last_name": "Norbert Weiss, MD", 
                    "phone": "+493514583659"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4tsklinikum Carl Gustav Carus"
                }, 
                "investigator": {
                    "last_name": "Norbert Weiss, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "s.nikol@asklepios.com", 
                    "last_name": "Sigrid Nikol, MD", 
                    "phone": "+49401818852401"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "ASKLEPIOS Klinik St. Georg"
                }, 
                "investigator": {
                    "last_name": "Sigrid Nikol, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zimlichman@wolfson.health.gov.il", 
                    "last_name": "Reuven Zimlichman, MD", 
                    "phone": "972-54-7525855"
                }, 
                "facility": {
                    "address": {
                        "city": "Holon", 
                        "country": "Israel", 
                        "zip": "58100"
                    }, 
                    "name": "Edith Wolson Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany", 
                "Israel"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)", 
        "overall_official": [
            {
                "affiliation": "Clinical Trials of Texas, Inc. 7940 Floyd Curl drive, Suite 700, San Antonio, Texas 78229", 
                "last_name": "Douglas Denham, DO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tampa Bay Medical research, 3251 McMullen Booth Road, STE 303, Clearwater, FL 33761", 
                "last_name": "James Hampsey, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Duke University,Durham, North Carolina, 27705, USA", 
                "last_name": "Schulyer Jones, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Florida research Network, LLC 6800NW  9th Blvd Suite1, Gainesville, Florida 32605", 
                "last_name": "Bret Weichmann, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cardiovascular Institute, Mount Sinai School of Medicine , One Gustave L. Levy Place, New York, NY 10029", 
                "last_name": "Jeffrey W Olin, DO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cardiovascular Division, MMC 508, University of Minnesota Medical school, Minneapolis, MN 55455", 
                "last_name": "Alan T Hirsch, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Kentucky, Lexington, KY 40506-0057", 
                "last_name": "Sibu P. Saha, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Omega Medical Research, Warwick, RI 02886", 
                "last_name": "David L Fried, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Franziskus-Krankenhaus, Berlin Germany", 
                "last_name": "Andr\u00e9 Schmidt-Lucke, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universit\u00e4tsklinikum  Carl Gustav Carus, Dresden, Germany", 
                "last_name": "Norbert Weiss, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "ASKLEPIOS Klinik St. Georg, Hamburg Germany", 
                "last_name": "Sigrid Nikol, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Turkey Creek Medical Center, Knoxville TN 37934", 
                "last_name": "Malcolm Foster, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "DMI Research, 6699 90th Ave. North, Pinellas Park FL", 
                "last_name": "Kathleen Cullen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital of the University of Pennsylvania, Philadelphia, PA 19104", 
                "last_name": "Mohler Emile, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Aiyan Diabetes Center, Evans, GA 30809", 
                "last_name": "Nadarajah Janaki, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Edith Wolfson Medical Center,62 HaLohamim Street, Holon, Israel", 
                "last_name": "Reuven Zimlichman, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Log ratio of week 52 maximal walking distance(MWD)to baseline MWD", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679990"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pluristem Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pluristem Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}